FCGBP_Fcgbp Inhibitors
FCGBP inhibitors encompass a range of compounds that indirectly decrease the functional activity of the glycoprotein FCGBP through various biochemical and cellular mechanisms. These compounds target different aspects of cellular function, from glycosylation processes to signaling pathways that ultimately contribute to the regulation of FCGBP activity. For instance, Phloretin works by inhibiting GLUT2 transporters, thus affecting the glucose availability necessary for proper glycosylation of proteins like FCGBP. In contrast, GW4869 acts by inhibiting neutral sphingomyelinase, leading to decreased ceramide production, which plays a role in inflammatory signaling pathways that can influence FCGBP expression.
Other compounds, such as LY294002 and AG490, target specific signaling cascades like the PI3K/Akt pathway and JAK/STAT pathway, respectively. Inhibition of these pathways can lead to a reduction in the expression of proteins involved in immune responses, including FCGBP. D-Mannitol's influence on protein glycosylation due to osmotic changes, Brefeldin A's blockade of protein transport, and Curcumin's suppression of NF-kB also contribute to the indirect inhibition of FCGBP. This diverse array of mechanisms showcases the complex regulation of FCGBP activity and how various chemical entities can contribute to its functional decrease without directly targeting the protein itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
Phloretin, a dihydrochalcone flavonoid, inhibits GLUT2, impeding glucose transport into cells. Since glycosylation is a glucose-dependent process and FCGBP is a heavily glycosylated protein, phloretin can indirectly inhibit FCGBP's function by disrupting proper glycosylation. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 disrupts the production of ceramide by inhibiting neutral sphingomyelinase. With ceramide implicated in cell signaling associated with inflammation, GW4869's effect can result in reduced inflammatory signaling, potentially leading to decreased expression or activity of FCGBP. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, leading to the suppression of the PI3K/Akt pathway. This pathway is involved in survival and proliferation, and its inhibition can affect immune response proteins' expression, including FCGBP, leading to its functional decrease. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 targets JAK2/STAT signaling, a pathway crucial for immune response gene expression. By inhibiting this pathway, AG490 can lead to reduced expression of immune-related proteins, potentially including FCGBP. | ||||||
D(−)Mannitol | 69-65-8 | sc-203020A sc-203020 | 50 g 100 g | $10.00 $19.00 | 2 | |
D-Mannitol, a sugar alcohol, alters cellular osmolarity, affecting protein glycosylation. Misregulated glycosylation can indirectly inhibit FCGBP's function, as its activity is glycosylation-dependent. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A blocks protein transport between the endoplasmic reticulum and Golgi apparatus. This disrupts glycoprotein processing, potentially leading to the misfolding and functional inhibition of FCGBP. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin inhibits NF-kB, a transcription factor involved in immune response. Its inhibition can decrease FCGBP expression due to reduced transcriptional activation of immune-related proteins. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein acts as a tyrosine kinase inhibitor. By suppressing cellular pathways essential for immune regulation, genistein can indirectly inhibit the function and expression of FCGBP. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Wiskostatin inhibits N-WASP, disrupting the actin cytoskeleton and vesicle trafficking. This can lead to impaired transport and function of glycoproteins, including FCGBP. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, affecting cell growth and survival pathways. This can lead to a downregulation of immune response proteins' expression, potentially including FCGBP. | ||||||